ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 45
УЖМБС 2018, 3(3): 101–105
Clinical Medicine

Influence of Intraperitoneal Chemotherapy on the Hormonal Status of Patients with Ovarian Cancer

Neffa M. Iu.

World science keeps trying to improve the effectiveness of treating malignant ovarian tumors, taking into account the fact that the death rate from this pathology takes a stable first place in oncological gynecology. There is a constant search for algorithms for screening and early diagnosis, as well as for improving the surgical treatment of this type of tumor. Clinical experience suggests that the detection of early stages of malignant ovaries tumors is more likely an exception than the rule. Hidden, asymptomatic clinical course; lack of clear ideas about etiology and pathogenesis; early and intensive universal metastasis; high degree of malignancy of the tumor – all these lead to the fact that 70-90% of patients with ovarian cancer (hereinafter – OC) are detected in the III-IV stage of the disease. That is why 5-year survival at all stages of the tumor process does not exceed 30%. Recent publications analysis suggests that the issues of overcoming the OC resistance to used drugs and their combinations, as well as regimens and modes of administration remain the subject of ongoing discussions in the world of scientific oncology. The interest of researchers is mainly concentrated on studying and developing new drugs that can not only improve the effectiveness of treatment, but also not reduce the life quality of these patients. In modern oncology this indicator is becoming increasingly important and is in line with such criteria for assessing the effectiveness of treatment as survival, duration of the disease-free period, median survival, etc. The tumor process in the body leads to violations of the regulation mechanisms by adaptation systems, and ongoing treatment deepens the already existing changes. In the literature there is more and more information about the research aimed at studying the peculiarities of hormonal regulation of the general adaptation reaction of cancer patients, as well as various attempts to correct it. This article considers the perspectives of using different variants of drug administration in adjuvant mode in patients with advanced ovarian cancer. The author studied and assessed the impact on the hormonal status of patients, as one of the mechanisms for regulating the processes of organism adaptation, using a regional mode of drug administration. In this research, we studied the dynamics of blood serum indices of a number of hormones that are considered to reflect the body's response to stress. Trends in hormonal status have been established depending on the effects of acute stress factors, such as surgical intervention and drug therapy in combination therapy. We also analyzed the influence of chronic stress factor as a tumor itself on the studied indicators. It was shown that with intraperitoneal administration of chemotherapy drugs, the change in the levels of the studied hormones in the blood serum of OC patients was comparable with the changes revealed in the study of the corresponding parameters in patients using the traditional mode of drug administration. Further studies are needed in this direction to allow individualization of therapeutic approaches in patients with advanced OC.

Keywords: ovarian cancer, intraperitoneal chemotherapy, hormonal status, adaptation reaction, stress

Full text: PDF (Rus) 199K

  1. Garkavi LKh, Kvakina EB, Kuzmenko TS. Antistressornye reaktsii i aktivatsionnaya terapiya. M: Imedis, 1998. 655 s. [Russian]
  2. Garkavi LKh, Shikhlyarova AN, Barsukova LM, i dr. Vzaimootnoshenie opukholi i organizma pri razvitii razlichnykh nespetsificheskikh adaptatsionnykh reaktsiy. Tezisy dokladov II sezda onkologov stran SNG. Kiev, 2000. s. 39. [Russian]
  3. Perevodchikova NI. Protivoopukholevaya khimioterapiya. M: Meditsina, 2015. 376 s. [Russian]
  4. Aghajanian C, Finkler N, Rutherford T, Smith DA, Yi J, Parmar H, Nycum LR, Sovak MA. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarien (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Clin Oncol. 2012; 29: Abstr. LBA5007.
  5. Asadollahi R, Hyde C, Zhong X. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol. Oncol. 2013; 118 (1): 81-7.
  6. Burger R, Brady M, Bookman M, Walker JL, Homesley HD, Fowler J, Monk BJ, et al. Phase III trial of bevacizumab (bev) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2012; 28: Abstr. LBA 1.
  7. Best C, Pratt H. Diagnosis and treatment of ovarian cancer. Nurs Times. 2009; 95: 6-7.
  8. Crawford S, Brunskill P. Guidelines for the management of ovarian cancer. Br J Obstet Gynecol. 2011; 107: 1059-60.
  9. Chambers S, Chambers J, Davis C, Kohorn EI, Schwartz PE, Lorber MI, Handschumacher RE, Pizzorno G. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and ctclosporine in refractory ovarian cancer patients. J Clin Oncol. 2012; 15: 945-52.
  10. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol. 2015; 13: 2961-7.
  11. Rothenberg M, Liu P, Braly P, et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol. 2013; 21: 1313-9.